Real-time assessment of neutrophil metabolism and oxidative burst using extracellular flux analysis.
extracellular flux analysis
glycolysis
immunometabolism
neutrophils
oxidative burst
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
10
2022
accepted:
05
04
2023
pubmed:
14
5
2023
medline:
16
5
2023
entrez:
14
5
2023
Statut:
epublish
Résumé
Neutrophil responses are critical during inflammatory and infective events, and neutrophil dysregulation has been associated with poor patient outcomes. Immunometabolism is a rapidly growing field that has provided insights into cellular functions in health and disease. Neutrophils are highly glycolytic when activated, with inhibition of glycolysis associated with functional deficits. There is currently very limited data available assessing metabolism in neutrophils. Extracellular flux (XF) analysis assesses real time oxygen consumption and the rate of proton efflux in cells. This technology allows for the automated addition of inhibitors and stimulants to visualise the effect on metabolism. We describe optimised protocols for an XFe96 XF Analyser to (i) probe glycolysis in neutrophils under basal and stimulated conditions, (ii) probe phorbol 12-myristate 13-acetate induced oxidative burst, and (iii) highlight challenges of using XF technology to examine mitochondrial function in neutrophils. We provide an overview of how to analyze XF data and identify pitfalls of probing neutrophil metabolism with XF analysis. In summary we describe robust methods for assessing glycolysis and oxidative burst in human neutrophils and discuss the challenges around using this technique to assess mitochondrial respiration. XF technology is a powerful platform with a user-friendly interface and data analysis templates, however we suggest caution when assessing neutrophil mitochondrial respiration.
Identifiants
pubmed: 37180154
doi: 10.3389/fimmu.2023.1083072
pmc: PMC10166867
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1083072Subventions
Organisme : Medical Research Council
ID : MR/L002736/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P021220/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T016736/1
Pays : United Kingdom
Informations de copyright
Copyright © 2023 Grudzinska, Jasper, Sapey, Thickett, Mauro, Scott and Barlow.
Déclaration de conflit d'intérêts
CM is a Scientific Advisory Board member of Lmito Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.